Business Context and Reporting Period
This Form 8-K Current Report was filed by EyePoint Pharmaceuticals, Inc. on November 1, 2021. The filing discloses the appointment of Jay S. Duker, M.D., as the Company's Chief Operating Officer (COO), effective November 1, 2021. Dr. Duker previously served as the Company's Chief Strategic Scientific Officer on a part-time basis and as an independent Board member from 2016 to 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Annual Base Salary: $500,000
- Target Annual Bonus: 50% of base salary ($250,000)
- One-Time Cash Award: $175,000 (subject to repayment terms if terminated without "Good Cause" or for "Cause" within one year)
- Stock Options: 305,000 shares at an exercise price of $11.47 per share
- Restricted Stock Units (RSUs): 15,258 units valued at $175,000
Material Changes
The primary material change is the transition of Dr. Duker from a part-time strategic role to a full-time executive position as COO. This appointment includes a new employment agreement and significant equity and cash compensation packages not previously disclosed in this capacity.
Guidance, Outlook, and Risks
The filing contains no financial guidance or outlook. Key terms and contingencies regarding the employment agreement include:
- Vesting Schedule: Options vest 25% on the first anniversary, followed by ratable monthly vesting through the fourth anniversary. RSUs vest fully on the first anniversary.
- Termination Provisions: In the event of termination without Cause or for Good Cause, Dr. Duker is entitled to 12 months of base salary, 100% of the target bonus, and health premium reimbursements.
- Change of Control: If termination occurs within 30 days prior to or 18 months following a Change of Control, salary continuation extends to 18 months, and unvested equity awards accelerate immediately.
- Restrictions: Dr. Duker is subject to non-compete, non-solicitation, and confidentiality agreements during and after employment.
Investor Verification Checklist
- Verify the total potential equity value of the 305,000 options and 15,258 RSUs based on current market prices versus the grant date values.
- Review the specific definitions of "Good Cause" and "Cause" in the Employment Agreement (Exhibit 10.1) to understand the conditions for the $175,000 one-time cash award repayment.
- Assess the impact of the 18-month salary continuation and full equity acceleration in a Change of Control scenario on future M&A negotiations.
- Confirm the vesting timeline for the options to understand the long-term retention incentives.